Group II p21-activated kinases (PAKs) are identified as regulators of regional vulnerability to α-synuclein pathology in Parkinson's disease models.
- Open access
- 5 cites
Moving in medRxiv, bioRxiv, Stem cell research, Cellular & molecular immunology, EMBO Journal and Nature Neuroscience.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
Group II p21-activated kinases (PAKs) are identified as regulators of regional vulnerability to α-synuclein pathology in Parkinson's disease models.
Elevated ABCA1 expression in the substantia nigra is linked to cholesterol overload and neurodegeneration in Parkinson's disease mouse models and postmortem brains.
CRISPR/Cas9 editing successfully corrected the LRRK2 I1371V mutation in a Parkinson's disease patient-derived iPSC line, creating an isogenic control line with confirmed genetic integrity.
Distinct tau polymorphs in Alzheimer’s disease, PSP, and DLB associate with unique protein interaction networks, with 493 high-confidence interactors identified.
The G2019S mutation in LRRK2 enhances NADPH oxidase-2 activity in neutrophils, improving bacterial infection control in mice by 2- to 3-fold.
Journals this month
Topics moving, week to 23 Oct 2026